CompletedPHASE1, PHASE2NCT02077361

An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

Studying Choroideremia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Alberta
Principal Investigator
Ian M MacDonald, MD, CM
University of Alberta
Intervention
rAAV2.REP1 vector(genetic)
Enrollment
6 enrolled
Eligibility
18 years · MALE
Timeline
2015 – 2022

Study locations (1)

Collaborators

Alberta Innovates Health Solutions · Canada Foundation for Innovation · Canadian Institutes of Health Research (CIHR) · Choroideremia Research Foundation Canada · Foundation Fighting Blindness · Imperial College London · University of Oxford

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02077361 on ClinicalTrials.gov

Other trials for Choroideremia

Additional recruiting or active studies for the same condition.

See all trials for Choroideremia →

← Back to all trials